
Peer reviewed version

Link to published version (if available):
10.1136/thoraxjnl-2018-212380

Link to publication record in Explore Bristol Research
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via BMJ at https://thorax.bmj.com/content/74/4/354. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
RESPECT-Meso CONSORT Flow Diagram

Assessed for eligibility (n=687)

513 excluded
- 170 declined to participate
- 344 did not meet inclusion criteria
  - 96 ECOG PS >2
  - 39 referral to SPC at time of diagnosis
  - 31 known malignancy within last 5 years
  - 35 diagnosis of mesothelioma >6 weeks
  - 40 participation in another trial
  - 11 commenced chemotherapy prior to consent
  - 14 significant other comorbidity
  - 6 significant psychological comorbidity
  - 22 out of catchment area
  - 42 Not malignant pleural mesothelioma
  - 5 died during screening
  - 2 other (non-English speaking; not stated)

Randomised (n=174)

Allocated to intervention (n=87)
- Received allocated intervention (n=83)
- Did not receive allocated intervention (ineligible) (n=1)

Allocated to control (n=87)

Lost to follow-up (n= 7) 2 withdrew, 5 died
Discontinued intervention (unable to attend clinic appointments) (n=3)

Lost to follow-up (n=10) 4 withdrew, 6 died.

Allocated to intervention (n=87)

Analysed (n=75)
- Excluded from analysis (n=5) Did not attend 12 week visit (n=3); insufficient data from EORTC C30 (n=2)

Analysed (n=73)
- Excluded from analysis (n=4) Did not attend 12 week visit (n=3); insufficient data from EORTC C30 (n=1)